ArticleJournal of gastroenterology and hepatology2025
Development and Validation of a New Prediction Criteria for Neoadjuvant Chemotherapy Response in Locally Advanced Gastric Cancer Based on Ferroptosis-Related Biomarkers.
Article in Journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epigenetic and post-translational regulatory networks of ferroptosis in the tumor immune microenvironment.Experimental hematology & oncology · 2026Review
- Development and Validation of a New Prediction Criteria for Neoadjuvant Chemotherapy Response in Locally Advanced Gastric Cancer Based on Ferroptosis-Related Biomarkers.Journal of gastroenterology and hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe efficacy of neoadjuvant chemotherapy (NAC) combined with surgery and postoperative adjuvant chemotherapy in improving the prognosis of locally advanced gastric cancer (LAGC) has been confirmed. Nevertheless, there is still no effective tool to predict the response to NAC in gastric cancer patients.
methodsThis study included a total of 184 patients (118 in the training cohort and 66 in the testing cohort) treated with oxaliplatin + fluorouracil-based NAC from January 2010 to July 2022. Immunohistochemistry staining of biomarkers was carried out on the endoscopy biopsy specimens before receiving treatment. Logistic regression was performed to explore the predictive biomarkers of response to NAC, and internal verification was carried out by using the bootstrap method.
resultFerroptosis increased significantly in NAC-sensitive LAGC. Among the molecular markers related to ferroptosis, Fe
conclusionThis study revealed the critical value of biomarkers related to ferroptosis serving as novel predictive biomarkers for patients with LAGC receiving NAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.